Cataract Surgery With Glaucoma: Eye Pressure, Lens Choice, MIGS and Recovery

Most people with glaucoma can have cataract surgery, and it usually clears the blur caused by the cataract. It cannot repair the optic nerve, so side vision already lost to glaucoma does not come back. The operation often lowers eye pressure a little: across 32 studies of open-angle glaucoma, pressure was about 12% to 15% lower in the first two years after surgery and 9% lower at three years. [78] Pressure can also jump in the first hours after surgery, so people with glaucoma need an early pressure check. [36] People with mild to moderate open-angle glaucoma may be offered a minimally invasive glaucoma procedure (MIGS), such as an iStent or Hydrus microstent, during the same operation, which can mean fewer drops afterward. [81, 82] The main decisions are which lens to choose, whether to add a glaucoma procedure, and how pressure will be watched while the eye heals.

Key Takeaways

• Glaucoma does not usually stop you from having cataract surgery. The surgeon checks your eye pressure, optic nerve, visual field and drainage angle first, and plans around them.
• Vision blurred by the cataract usually improves: across all cataract surgery, about 9 in 10 people see better afterward. [84] With glaucoma, how much you gain depends on the health of the optic nerve, and side vision already lost to glaucoma does not come back. [4]
• In open-angle glaucoma the pressure drop is usually modest and may fade over a few years. In angle-closure glaucoma, removing the lens can widen the drainage angle, and pressure tends to fall more: by about 6 mmHg on average in one review, against about 3 mmHg in open-angle glaucoma. [78, 87, 85]
• Adding a Hydrus microstent to cataract surgery raised the share of people who needed no drops from about half to more than three quarters in two trials. The evidence for the iStent is weaker. [81, 82]
• A standard (monofocal) lens, with toric correction for astigmatism if needed, suits most eyes with glaucoma. Multifocal and extended depth of focus lenses need careful selection because glaucoma can already reduce contrast. [83]
• Keep using your glaucoma drops unless your surgeon tells you otherwise. Do not cut down the steroid drops after surgery on your own, even though they can raise pressure in some people; tell your surgeon instead.

For glaucoma as a whole, including the types, symptoms, tests and treatments, read our glaucoma guide. How the two conditions differ, and how to tell their symptoms apart, is covered in our guide to glaucoma vs cataracts.

Cataract surgery with glaucoma at a glance

For someone with both conditions, planning involves three related decisions: whether removing the cataract is likely to help, which intraocular lens best fits the eye and daily needs, and whether a glaucoma procedure should be performed at the same time. The answers depend on the type and stage of glaucoma, the pressure target and the remaining visual function. [1, 2, 3]

A successful operation is not defined only by reading smaller letters on a chart or using fewer drops. Glare, contrast, useful peripheral vision, spectacle needs and the stability of the glaucoma also matter. A careful consultation should explain which limitations are likely to improve and which may remain.

Separating the cataract from the glaucoma

A cataract clouds the natural lens through which light enters the eye. Glaucoma damages the optic nerve. Both can affect vision, and their symptoms may overlap. A patient may describe blur, poor night vision or difficulty reading without being able to identify which condition contributes most.

The surgeon examines the lens, retina, optic nerve and visual field to estimate the likely benefit of cataract removal. The estimate may be less precise if a dense cataract prevents a clear view or reduces test quality. That uncertainty should be discussed before surgery rather than discovered only after the lens has been removed.

Some people with advanced glaucoma still gain useful improvement from cataract surgery. The remaining nerve function, central vision and other eye conditions influence the result. An expectation of improvement is different from a promise of normal vision, and the decision should be connected to the tasks that matter to that particular patient. [4]

Why contrast matters as much as the eye chart

Contrast sensitivity is the ability to distinguish an object from its background when the difference between them is small. It helps with tasks such as seeing a curb in dim light or reading faded print. Glaucoma can affect contrast even when high-contrast visual acuity remains relatively good. [2, 3, 5, 6]

This matters when choosing an artificial lens. A design that expands the range of focus may involve optical tradeoffs, and those tradeoffs can matter more in an eye with reduced visual reserve. The consultation should include night driving, glare tolerance, reading needs and the lighting conditions in which the patient struggles.

Two people with the same chart acuity may therefore prefer different lens strategies. One may prioritize sharp distance vision and accept reading glasses. Another with carefully selected early disease may value a wider range of focus. Neither preference should override the limitations imposed by the health of the optic nerve.

What an intraocular lens can and cannot do

An intraocular lens, or IOL, replaces the natural lens removed during cataract surgery. Its power is calculated using measurements of the eye and a planned focusing target. It can correct some refractive error, but it cannot repair the optic nerve or remove an established visual-field defect.

The term premium lens usually refers to particular optical features or pricing arrangements. It is not a guarantee that the lens is medically preferable for every patient. A more expensive option may be a poor match for an eye with advanced disease or a person especially troubled by glare. [7, 8, 9]

Ask the surgeon to describe the expected result with and without glasses at the distances you use most. A lens discussion becomes more useful when it starts with specific tasks, such as reading medication labels, working at a computer or driving at dusk, instead of a broad promise of spectacle freedom.

Monofocal lenses and the focusing target

A standard monofocal IOL is designed primarily for one focusing range. Many patients choose a distance target and use glasses for near work. Others may prefer a different target after discussing their habits and the other eye. The choice of target is separate from the decision to operate.

Some monofocal designs aim to improve intermediate performance while retaining a broadly monofocal approach. Studies of these lenses provide information about visual outcomes, but results in general cataract populations should not automatically be transferred to eyes with substantial glaucoma damage. The exact design and the condition of the eye both matter. [10, 11, 12]

Monovision uses different focusing targets in the two eyes to reduce dependence on glasses for some tasks. It may affect depth perception or binocular comfort and is not suitable for everyone. A history of successful monovision can help the discussion, but a patient should understand the intended compromise before surgery. [13]

Toric lenses for astigmatism

A toric IOL corrects a component of regular corneal astigmatism. Toric describes astigmatism correction; it does not necessarily mean multifocal. A lens can be both toric and monofocal. This distinction prevents confusion when a patient is told that glaucoma makes certain optical designs less attractive.

Studies in glaucoma patients, including people undergoing combined cataract and angle surgery, have reported refractive and astigmatism outcomes with toric lenses. Suitability depends on reliable corneal measurements, the type of astigmatism, lens stability and the planned operation. A toric lens cannot correct blur arising from optic nerve damage. [14, 15, 16, 17, 18]

The surgeon also considers whether another planned glaucoma procedure may change the eye's shape or refractive result. Reducing astigmatism can be valuable, but no calculation guarantees that glasses will never be needed. Ask what residual prescription is realistic and how it would be managed. [19]

Multifocal and trifocal lenses require careful selection

Multifocal and trifocal lenses distribute light to provide useful focus at more than one distance. They can reduce spectacle dependence in suitable patients, while also producing halos, glare or reductions in some aspects of contrast. Lens designs differ, and results from one design do not apply identically to all others. [20, 21, 22, 23, 24]

Because glaucoma may already reduce contrast and visual-field reserve, these tradeoffs deserve particular attention. More advanced or unstable glaucoma generally makes the choice more difficult. A favorable result in a selected early-disease group is not evidence that the same approach is suitable for an eye with central field loss.

A 2023 systematic review found only 12 studies of premium lenses (toric, multifocal and extended depth of focus) in glaucoma, 399 eyes in all, and some included very few people with glaucoma. They reported good distance vision without glasses and high satisfaction. The reviewers found the best results in people with high eye pressure or early, well-controlled glaucoma, and not enough evidence on safety in advanced glaucoma. They listed the type and severity of field loss, the glaucoma subtype, dry eye, changes from earlier glaucoma surgery and the reliability of future tests as the main things to weigh. [83] A few more small studies have been published since, mostly in mild or early glaucoma.

Research has also examined how multifocal optics influence automated visual-field measurements. A change in a test after implantation may partly reflect the optical system, so future monitoring needs to account for it. Lens selection is therefore relevant not only to everyday vision but also to the interpretation of subsequent tests. [25, 26]

Extended depth of focus lenses

Extended depth of focus, or EDOF, lenses aim to provide a broader useful focusing range. The category includes different optical designs. Describing a lens as EDOF does not by itself specify its contrast performance, night symptoms or suitability for glaucoma. The surgeon should discuss the actual design under consideration.

A prospective study of a non-diffractive EDOF lens included 26 patients with mild open-angle glaucoma and reported favorable distance and intermediate outcomes over a short follow-up period. Many participants also received a trabecular microbypass stent. The study was small and lacked the kind of randomized long-term comparison needed to generalize confidently to more advanced glaucoma. [27]

A separate retrospective comparison in early glaucoma found better intermediate and near performance with the studied EDOF lens than with monofocal lenses, alongside reported differences in spectacle independence. It was nonrandomized and involved a small selected group. These findings support a conversation about carefully selected candidates rather than a universal recommendation. [28]

Other case series and comparative reports add useful experience but do not eliminate uncertainty about future disease progression. A lens that suits the eye today must also be considered in the context of the patient's likely long-term visual needs. [29, 30, 31]

How cataract surgery affects eye pressure

Removing the natural lens can lower pressure in some eyes, but the effect varies with the glaucoma type, starting pressure and anatomy. A cataract operation alone should not be assumed to provide enough pressure reduction for every patient. The surgeon compares the expected effect with the pressure target needed to protect the nerve. [1, 32]

In a 2017 analysis of 32 studies (1,826 people with open-angle glaucoma), pressure was 12% lower than before surgery at six months, 14% at one year, 15% at two years and 9% at three years, and people used slightly fewer drops: about half a drop fewer per person in the first year, falling to 0.16 at three years. [78] A 2024 analysis of the cataract-only groups of nine randomized trials (502 people with open-angle glaucoma or high eye pressure) found pressure 3.8 mmHg lower a year after surgery, and 5.3 mmHg lower in trials that stopped drops before measuring it. [79] In the Ocular Hypertension Treatment Study, 63 eyes with high pressure but no glaucoma, not using pressure drops, had pressure 16.5% lower after cataract surgery, and it stayed lower for at least three years. [80]

Angle-closure disease is a distinct situation because the lens contributes to the crowded anatomy in the front of the eye. Open-angle glaucoma involves a different clinical problem. A treatment result from one group should not be applied indiscriminately to the other. [33, 34, 35]

In the EAGLE trial of people aged 50 or over with angle-closure glaucoma, or angle closure with very high pressure, removing the clear lens worked better than laser iridotomy with drops, and was more cost-effective. The people in EAGLE did not have cataracts, and the gain was modest: pressure about 1.2 mmHg lower and slightly better quality of life after three years. [85] Our guide to angle-closure glaucoma explains when lens removal is offered.

Pressure can also rise temporarily after surgery. Studies have documented early elevations in patients with glaucoma or exfoliation syndrome. The postoperative plan may therefore include specific pressure checks and medication instructions. A longer-term possibility of lower pressure does not remove the need to monitor the immediate recovery period. [36, 37]

In one small randomized study of 122 people having uncomplicated cataract surgery, pressure went above 25 mmHg within the first day in 55% of eyes with well-controlled glaucoma and 27% of eyes with exfoliation syndrome when no pressure-lowering drop was given at the end of surgery, and in none of the eyes without these conditions. Most spikes happened about 4 hours after surgery, and average pressure was below 20 mmHg in every group by the next day. A single drop of timolol at the end of surgery prevented spikes above 30 mmHg, but smaller rises above 25 mmHg still happened in 14% of eyes with glaucoma. [36]

What MIGS adds to the discussion

Minimally invasive glaucoma surgery, often called MIGS, includes a range of procedures intended to reduce pressure or medication burden with approaches that differ from traditional filtering surgery. Some are commonly combined with cataract surgery. They are not one interchangeable operation, and not all use an implanted device. [38, 39, 40]

The surgeon should name the proposed procedure and explain its mechanism, expected benefit and limitations. Important questions include whether the drainage angle is suitable, whether the expected reduction meets the pressure target, and what will happen if drops remain necessary. A procedure may reduce medication burden without achieving the very low pressure required in a different clinical situation.

Many angle-based MIGS options are considered in selected patients with open-angle disease. Advanced glaucoma or an especially low target may call for another strategy. The word minimally does not mean risk-free or automatically adequate. The operation must fit the disease rather than being added merely because cataract surgery is already planned.

What combined-surgery trials contribute

Randomized studies have compared cataract surgery with and without particular trabecular implants. They help estimate the additional effect of the tested device beyond cataract removal alone. The findings belong to that procedure, trial population and follow-up period; they should not be treated as proof that every MIGS technique produces the same results. [41, 42]

For the Hydrus microstent, a Cochrane review of two trials (about 640 people, mostly mild to moderate glaucoma) found moderate-certainty evidence that adding it to cataract surgery raised the share of people who needed no drops from about half to more than three quarters at one and two years, and, when measured after drops were paused, lowered pressure at two years by about 2 mmHg more than cataract surgery alone. Most people in these trials had pressure that was already controlled on drops. [81] In the HORIZON trial, 66% of eyes that had the stent were off drops at five years, against 46% after cataract surgery alone. [42]

For the iStent, a Cochrane review judged the evidence to be of very low certainty: people who had the iStent with cataract surgery were about 1.4 times as likely to be drop-free at 6 to 18 months, and used about 0.4 of a drop fewer on average. [82] A 2026 analysis of five trials (915 eyes) found much the same, and concluded that the main benefit is fewer drops rather than extra pressure lowering. [88] In the larger trial of the newer iStent inject (505 eyes), pressure measured after drops had been paused for the test was at least 20% lower than at the start in 75.8% of eyes at two years, against 61.9% after cataract surgery alone. [86] All these trials were funded by the device makers.

A five-year post hoc analysis of visual fields from the HORIZON randomized trial found slower average field decline in the group assigned to cataract surgery with a Hydrus microstent than in the cataract-only group. This is relevant evidence about functional outcomes. Because it was a secondary analysis in a defined trial population, it does not establish that all patients or all glaucoma procedures will experience the same benefit. [43]

When discussing a study, ask whether its participants had disease similar to yours and whether the outcome was pressure, medication use, visual-field change or another measure. These outcomes can all matter, but they are not interchangeable. A reduction in drops should be interpreted alongside the continuing need to preserve vision.

Combined surgery versus separate operations

Combining procedures may allow the surgeon to address the cataract and pressure control during one operation. A staged approach may be preferable when the pressure problem needs to be addressed first, when refractive planning is particularly complex or when the best sequence depends on the response to an earlier procedure.

Studies comparing combined cataract and filtering operations with other approaches have examined pressure control, complications and refractive outcomes. They do not yield one sequence that is best for every eye. The urgency of glaucoma control, lens opacity, previous surgery and patient circumstances all influence the decision. [44, 45, 46, 47, 48]

Traditional trabeculectomy or a drainage implant may be discussed when the required pressure reduction exceeds what a proposed angle procedure is likely to achieve. These operations have their own risks and follow-up demands. The surgeon should explain why the recommended sequence fits the target rather than present all procedures as equivalent menu choices.

Previous glaucoma surgery can affect lens calculations

Pressure-lowering surgery may alter aspects of eye shape or measurement, and cataract surgery in an eye with a previous filtering procedure requires attention to that history. Studies have examined changes in axial length, corneal curvature and refractive prediction after trabeculectomy or drainage surgery. [49, 50, 51, 52, 53]

These findings do not mean an accurate result is impossible. They mean the surgeon may need additional records, repeat measurements or a different expectation about refractive precision. The size of a pressure change and the timing between operations can be relevant. [54, 55, 56, 57, 58, 59]

If you have had glaucoma surgery, bring the operative history if the cataract surgeon does not already have it. Ask whether the existing drainage site changes the surgical plan or follow-up. A previous successful procedure still needs to be considered when planning the next one. [60]

Dry eye and measurement quality before surgery

A stable tear film helps produce reliable corneal measurements. People using long-term glaucoma drops may also have ocular-surface symptoms that affect comfort or measurement quality. Preparing the surface before final lens calculations can be part of obtaining a dependable plan. [61, 62, 63]

This preparation should be coordinated with the glaucoma regimen. Do not stop pressure-lowering drops simply to make the surface feel better before measurements. Tell the team about burning, fluctuating blur and difficulty tolerating medication so that both pressure control and surface care can be addressed.

A repeated measurement is often a quality step. If readings disagree, the surgeon may want to resolve the cause before committing to a lens power or astigmatism correction. That is especially relevant when a patient has high expectations for vision without glasses.

Pseudoexfoliation and other additional considerations

Pseudoexfoliation can affect the pupil and the structures supporting the natural lens. In some eyes, these factors make cataract surgery more complex and influence the choice or support of the implanted lens. Published studies describe operative difficulties and later lens-related outcomes in this group. [64, 65, 66, 67, 68]

The surgeon may discuss additional devices or techniques if the supporting fibers, called zonules, appear weak. These measures are selected during planning or surgery according to the findings. A general article cannot determine whether they will be needed in an individual eye. Our guide to pseudoexfoliation glaucoma explains the condition.

Other factors, including retinal disease, corneal problems, previous refractive surgery and marked differences between the eyes, can also affect the plan. The glaucoma diagnosis is important, but it should not crowd out assessment of the rest of the visual system.

What recovery may involve

The National Eye Institute says the surgery lasts about an hour and is almost painless, that most people are completely healed within 8 weeks, and that you may need to avoid touching the eye, bending over and lifting heavy things for a few weeks. You will be given drops to help the eye heal and may need to wear an eye shield. [84] With glaucoma, add an early pressure check, on the day of surgery or the next day depending on how advanced your glaucoma is, and clear instructions about your usual drops.

The postoperative instructions should state which preexisting glaucoma drops to continue, which to pause if instructed, and how to use the new postoperative medicines. Do not assume that successful combined surgery means all glaucoma treatment stops immediately. The plan may change as pressure and healing are assessed.

Steroid drops used after surgery can themselves raise pressure in susceptible patients. Inflammation, retained surgical material and other postoperative factors may also contribute to a pressure change. The surgeon needs to identify the cause rather than have the patient independently reduce the anti-inflammatory treatment.

Ask when pressure will be checked, when activity restrictions will be reviewed and when a new spectacle prescription is likely to be appropriate. Recovery varies by procedure and eye. A fixed timetable found online may not fit a combined operation or a patient with advanced disease.

Vision expectations should be specific

Before surgery, identify two or three tasks you hope will improve. Examples include seeing faces more clearly, reducing glare from headlights or reading with better lighting and glasses. Ask which goals are realistic given the cataract and which may remain limited by the visual field or optic nerve.

Better central clarity may not restore missing peripheral awareness. A person can be pleased with brighter vision while still needing adaptations for mobility or reading. Low-vision support may remain useful even when the cataract operation is technically successful and the lens is positioned appropriately.

The final spectacle prescription can differ from the calculated target. Studies of cataract and combined glaucoma surgery document this variability. Discuss how residual refractive error would be managed and whether the expected benefit still makes sense if some glasses remain necessary. [69, 70, 71, 72, 73, 74, 75, 76]

A hypothetical planning conversation

Consider an invented example of someone with mild stable open-angle glaucoma, a visually significant cataract and difficulty using several drops. The surgeon may discuss cataract removal with a suitable lens and a particular angle procedure, explaining that fewer drops are possible but not guaranteed. Lens options are considered alongside contrast, night driving and the likelihood of future progression.

Now consider an invented example of someone with advanced central field damage and pressure above the required target. The priority may be dependable pressure control, and the optical tradeoffs of a multifocal design may be less acceptable. A more substantial glaucoma operation or a staged approach may be considered. These examples illustrate the questions, not recommendations for any reader.

The same diagnosis can therefore lead to different plans. The decision should be traceable to the condition of the eye, the pressure target and the person's needs. It should not depend on a general rule that every glaucoma patient must receive one lens or that every cataract operation should include MIGS.

Where NRT may fit

Netra Restoration Therapy (NRT) at Netra Eye Institute does not treat cataracts or glaucoma, does not lower eye pressure, and cannot replace cataract surgery, drops, laser or glaucoma surgery. It does not restore any vision lost to glaucoma. After surgery and once glaucoma is medically stable, some people still struggle with scanning, reading or getting around because of field loss that was already there. Low-vision optometrists and occupational therapists can help with those tasks. If you choose NRT, it is offered only alongside that care and your glaucoma treatment, never in place of them.

Learn about Netra Restoration Therapy and low-vision rehabilitation.

Frequently asked questions

Can you have cataract surgery if you have glaucoma?

Yes. Most people with glaucoma can have cataract surgery, and some have it at the same time as a glaucoma procedure. The surgeon first checks that the pressure is controlled well enough, looks at the drainage angle and optic nerve, and plans the lens and follow-up around your glaucoma. Advanced glaucoma or very high pressure may change the order of operations.

Will cataract surgery lower my eye pressure?

Often a little. In people with open-angle glaucoma, pressure was about 12% to 15% lower in the first two years and 9% lower at three years across 32 studies, and people used slightly fewer drops. In angle-closure glaucoma, removing the lens can widen the drainage angle, and the fall is usually larger. The effect varies, so your glaucoma doctor keeps measuring pressure after surgery.

Should I have an iStent or other MIGS during cataract surgery?

It is worth asking about if you have mild to moderate open-angle glaucoma, especially if you use several drops. Adding a Hydrus microstent increased the share of people who needed no drops from about half to more than three quarters in two trials; evidence for the iStent is weaker. Most MIGS procedures lower pressure less than trabeculectomy or a tube, so they may not be enough for advanced glaucoma. [38, 39]

What is the best lens for cataract surgery if I have glaucoma?

There is no single best lens, but a monofocal lens, with toric correction for astigmatism if needed, suits most eyes with glaucoma. Multifocal and extended depth of focus lenses can reduce the need for glasses but may lower contrast and cause halos, which matters more when glaucoma has already reduced contrast or side vision. They are usually kept for selected people with early, stable glaucoma.

Can I stop my glaucoma drops after cataract surgery?

Not on your own. Some people need fewer drops afterward, but pressure can rise in the first days, and the steroid drops used after surgery can raise it too. Keep using your glaucoma drops exactly as your surgeon instructs, and let your glaucoma doctor decide whether any can be reduced once the eye has healed.

Is cataract surgery riskier if you have glaucoma?

Glaucoma adds a few specific risks: a pressure spike in the first hours, a pressure rise from steroid drops, and in eyes with pseudoexfoliation, a small pupil and weak lens supports that make surgery harder. A previous trabeculectomy also needs planning, because cataract surgery can make it drain less well in some eyes. [60] These risks are usually managed with extra pressure checks and surgical planning, and serious complications remain uncommon.

How long is recovery after cataract surgery with glaucoma?

Many people see more clearly within a few days, although vision can be blurry at first, and most are completely healed within about 8 weeks. Expect an early pressure check, on the day of surgery or the next day, then more visits than after cataract surgery alone, especially if a glaucoma procedure was added. A new glasses prescription usually waits until the eye has settled.

Can cataract surgery cause glaucoma?

It can raise eye pressure for a while, from inflammation, leftover gel used during surgery or a response to steroid drops, and this usually settles with treatment. Lasting glaucoma after adult cataract surgery is not common. Children are different: across 36 studies, about 7% developed glaucoma after surgery for cataracts they were born with, and about 14% of those left without a lens implant, so they need lifelong pressure checks. [89] Our guide to glaucoma vs cataracts covers this in more detail.

Will cataract surgery cure my glaucoma?

No. It may improve cataract-related vision and can affect pressure, but glaucoma still requires follow-up. Even when medication burden falls, the optic nerve and visual field need continued assessment. Existing nerve damage is not removed along with the cloudy lens.

Are premium lenses always unsuitable?

No universal statement fits every design and every stage of glaucoma. Selected patients with early stable disease may have options that would be less appropriate in advanced disease. Ask about the evidence for the exact lens and the tradeoffs relevant to your remaining contrast and field function.

Does MIGS mean I will never need drops again?

No. Some patients reduce medication use, while others continue drops or need additional treatment later. The intended goal should be explained before surgery. A good result may be improved pressure control on fewer medicines, rather than permanent freedom from every treatment.

Will I need new glaucoma tests after surgery?

The clinician may establish new postoperative imaging or field baselines after the eye has recovered, because removing a cataract and changing the optical system can affect test quality or measurements. The timing and interpretation depend on the individual record. An apparent improvement in a field index does not mean lost nerve tissue regrew. [25, 26, 77]

What symptoms require urgent contact?

Contact the surgical team urgently for increasing pain, marked redness, sudden or worsening vision loss, new flashes or a curtain-like shadow, severe eye pain or headache with nausea or vomiting, rainbow-colored halos around lights, or other symptoms identified in your discharge instructions. Do not assume that a major change is normal recovery or simply the glaucoma. If the surgical service cannot be reached, seek urgent ophthalmic care.

The bottom line

The most useful preoperative plan states the expected visual benefit, the lens target, the pressure-control strategy and the follow-up responsibilities. With glaucoma, each part supports the others. Clear expectations help patients judge the outcome by meaningful improvements while continuing the care needed to protect their remaining vision.

More on glaucoma

• Glaucoma vs Cataracts: Differences, Symptoms, Treatment and Having Both
• Glaucoma Surgery and Laser: SLT, MIGS, iStent, Trabeculectomy and Tube Shunts
• SLT Laser for Glaucoma: Selective Laser Trabeculoplasty Side Effects, Recovery and Results
• Angle-Closure (Narrow-Angle) Glaucoma: Symptoms, Emergency Signs and Treatment
• Pseudoexfoliation Glaucoma: Causes, Risks, Treatment and Cataract Surgery
• Glaucoma Eye Drops: Types, Medication List, Side Effects and How to Use Them
• When Is Cataract Surgery Needed? How to Decide
• Cataract FAQ: 85 Questions Answered
• Glaucoma: Symptoms, Causes, Treatment and Integrative Support

References and supporting research

Numbered citations identify sources connected to the text. The remaining entries provide relevant supporting research. Clinical trials, observational studies, laboratory research and professional guidance answer different questions; the size of this bibliography does not imply that every source provides equally strong evidence.

1. Ling J.D., Bell N.P. Role of Cataract Surgery in the Management of Glaucoma. Int. Ophthalmol. Clin. 2018;58:87–100. Source
2. Hawkins A.S., Szlyk J.P., Ardickas Z., Alexander K.R., Wilensky J.T. Comparison of contrast sensitivity, visual acuity, and Humphrey visual field testing in patients with glaucoma. J. Glaucoma. 2003;12:134–138. Source
3. Fatehi N., Nowroozizadeh S., Henry S., Coleman A.L., Caprioli J., Nouri-Mahdavi K. Association of Structural and Functional Measures With Contrast Sensitivity in Glaucoma. Am. J. Ophthalmol. 2017;178:129–139. Source
4. Fu L., Chan Y.K., Li J., Nie L., Li N., Pan W. Long term outcomes of cataract surgery in severe and end stage primary angle closure glaucoma with controlled IOP: A retrospective study. BMC Ophthalmol. 2020;20:160. Source
5. Richman J., Lorenzana L.L., Lankaranian D., Dugar J., Mayer J., Wizov S.S., Spaeth G.L. Importance of visual acuity and contrast sensitivity in patients with glaucoma. Arch. Ophthalmol. 2010;128:1576–1582. Source
6. Burton R., Crabb D.P., Smith N.D., Glen F.C., Garway-Heath D.F. Glaucoma and reading: Exploring the effects of contrast lowering of text. Optom. Vis. Sci. 2012;89:1282–1287. Source
7. Ichhpujani P., Bhartiya S., Sharma A. Premium IOLs in Glaucoma. J. Curr. Glaucoma Pract. 2013;7:54–57. Source
8. Yeu E., Cuozzo S. Matching the Patient to the Intraocular Lens: Preoperative Considerations to Optimize Surgical Outcomes. Ophthalmology. 2021;128:e132–e141. Source
9. Braga-Mele R., Chang D., Dewey S., Foster G., Henderson B.A., Hill W., Hoffman R., Little B., Mamalis N., Oetting T., et al. Multifocal intraocular lenses: Relative indications and contraindications for implantation. J. Cataract Refract. Surg. 2014;40:313–322. Source
10. Mencucci R., Cennamo M., Venturi D., Vignapiano R., Favuzza E. Visual outcome, optical quality, and patient satisfaction with a new monofocal IOL, enhanced for intermediate vision: Preliminary results. J. Cataract Refract. Surg. 2020;46:378–387. Source
11. Auffarth G.U., Gerl M., Tsai L., Janakiraman D.P., Jackson B., Alarcon A., Dick H.B. Clinical evaluation of a new monofocal IOL with enhanced intermediate function in patients with cataract. J. Cataract Refract. Surg. 2021;47:184–191. Source
12. Unsal U., Sabur H. Comparison of new monofocal innovative and standard monofocal intraocular lens after phacoemulsification. Int. Ophthalmol. 2021;41:273–282. Source
13. Evans B.J. Monovision: A review. Ophthalmic Physiol. Opt. 2007;27:417–439. Source
14. Ichioka S., Ishida A., Takayanagi Y., Manabe K., Matsuo M., Tanito M. Roles of Toric intraocular Lens implantation on visual acuity and astigmatism in glaucomatous eyes treated with iStent and cataract surgery. BMC Ophthalmol. 2022;22:487. Source
15. Takai Y., Sugihara K., Mochiji M., Manabe K., Tsutsui A., Tanito M. Refractive Status in Eyes Implanted with Toric and Nontoric Intraocular Lenses during Combined Cataract Surgery and Microhook Ab Interno Trabeculotomy. J. Ophthalmol. 2021;2021:5545007. Source
16. López-Caballero C., Sánchez-Sánchez C., Puerto B., Blázquez V., Sánchez-Pina J.M., Contreras I. Refractive outcomes of toric intraocular lens in combined trabecular micro bypass stent implantation and cataract surgery in glaucomatous eyes. Int. Ophthalmol. 2022;42:2711–2718. Source
17. Ichioka S., Manabe K., Tsutsui A., Takai Y., Tanito M. Effect of Toric Intraocular Lens Implantation on Visual Acuity and Astigmatism Status in Eyes Treated With Microhook Ab Interno Trabeculotomy. J. Glaucoma. 2021;30:94–100. Source
18. Brown R.H., Zhong L., Bozeman C.W., Lynch M.G. Toric Intraocular Lens Outcomes in Patients With Glaucoma. J. Refract. Surg. 2015;31:366–372. Source
19. Visser N., Bauer N.J., Nuijts R.M. Toric intraocular lenses: Historical overview, patient selection, IOL calculation, surgical techniques, clinical outcomes, and complications. J. Cataract Refract. Surg. 2013;39:624–637. Source
20. Artigas J.M., Menezo J.L., Peris C., Felipe A., Díaz-Llopis M. Image quality with multifocal intraocular lenses and the effect of pupil size: Comparison of refractive and hybrid refractive-diffractive designs. J. Cataract Refract. Surg. 2007;33:2111–2117. Source
21. Javitt J.C., Steinert R.F. Cataract extraction with multifocal intraocular lens implantation: A multinational clinical trial evaluating clinical, functional, and quality-of-life outcomes. Ophthalmology. 2000;107:2040–2048. Source
22. Martínez Palmer A., Gómez Faiña P., España Albelda A., Comas Serrano M., Nahra Saad D., Castilla Céspedes M. Visual function with bilateral implantation of monofocal and multifocal intraocular lenses: A prospective, randomized, controlled clinical trial. J. Refract. Surg. 2008;24:257–264. Source
23. Pieh S., Lackner B., Hanselmayer G., Zöhrer R., Sticker M., Weghaupt H., Fercher A., Skorpik C. Halo size under distance and near conditions in refractive multifocal intraocular lenses. Br. J. Ophthalmol. 2001;85:816–821. Source
24. Cao K., Friedman D.S., Jin S., Yusufu M., Zhang J., Wang J., Hou S., Zhu G., Wang B., Xiong Y., et al. Multifocal versus monofocal intraocular lenses for age-related cataract patients: A system review and meta-analysis based on randomized controlled trials. Surv. Ophthalmol. 2019;64:647–658. Source
25. Farid M., Chak G., Garg S., Steinert R.F. Reduction in mean deviation values in automated perimetry in eyes with multifocal compared to monofocal intraocular lens implants. Am. J. Ophthalmol. 2014;158:227–231.e221. Source
26. Aychoua N., Junoy Montolio F.G., Jansonius N.M. Influence of multifocal intraocular lenses on standard automated perimetry test results. JAMA Ophthalmol. 2013;131:481–485. Source
27. Ferguson T.J., Wilson C.W., Shafer B.M., Berdahl J.P., Terveen D.C. Clinical Outcomes of a Non-Diffractive Extended Depth-of-Focus IOL in Eyes with Mild Glaucoma. Clin. Ophthalmol. 2023;17:861–868. Source
28. Kerr N.M., Moshegov S., Lim S., Simos M. Visual Outcomes, Spectacle Independence, and Patient-Reported Satisfaction of the Vivity Extended Range of Vision Intraocular Lens in Patients with Early Glaucoma: An Observational Comparative Study. Clin. Ophthalmol. 2023;17:1515–1523. Source
29. Bissen-Miyajima H., Ota Y., Yuki K., Minami K. Implantation of diffractive extended depth-of-focus intraocular lenses in normal tension glaucoma eyes: A case series. Am. J. Ophthalmol. Case Rep. 2023;29:101792. Source
30. Sánchez-Sánchez C., Rementería-Capelo L.A., Puerto B., López-Caballero C., Morán A., Sánchez-Pina J.M., Contreras I. Visual Function and Patient Satisfaction with Multifocal Intraocular Lenses in Patients with Glaucoma and Dry Age-Related Macular Degeneration. J. Ophthalmol. 2021;2021:9935983. Source
31. Rementería-Capelo L.A., Lorente P., Carrillo V., Sánchez-Pina J.M., Ruiz-Alcocer J., Contreras I. Patient Satisfaction and Visual Performance in Patients with Ocular Pathology after Bilateral Implantation of a New Extended Depth of Focus Intraocular Lens. J. Ophthalmol. 2022;2022:4659309. Source
32. Law S.K., Riddle J. Management of cataracts in patients with glaucoma. Int. Ophthalmol. Clin. 2011;51:1–18. Source
33. Sun X., Dai Y., Chen Y., Yu D.Y., Cringle S.J., Chen J., Kong X., Wang X., Jiang C. Primary angle closure glaucoma: What we know and what we don’t know. Prog. Retin. Eye Res. 2017;57:26–45. Source
34. El Sayed Y.M., Elhusseiny A.M., Albalkini A.S., El Sheikh R.H., Osman M.A. Mitomycin C-augmented Phacotrabeculectomy Versus Phacoemulsification in Primary Angle-closure Glaucoma: A Randomized Controlled Study. J. Glaucoma. 2019;28:911–915. Source
35. Li S.W., Chen Y., Wu Q., Lu B., Wang W.Q., Fang J. Angle parameter changes of phacoemulsification and combined phacotrabeculectomy for acute primary angle closure. Int. J. Ophthalmol. 2015;8:742–747. Source
36. Levkovitch-Verbin H., Habot-Wilner Z., Burla N., Melamed S., Goldenfeld M., Bar-Sela S.M., Sachs D. Intraocular pressure elevation within the first 24 hours after cataract surgery in patients with glaucoma or exfoliation syndrome. Ophthalmology. 2008;115:104–108. Source
37. Krupin T., Feitl M.E., Bishop K.I. Postoperative intraocular pressure rise in open-angle glaucoma patients after cataract or combined cataract-filtration surgery. Ophthalmology. 1989;96:579–584. Source
38. Saheb H., Ahmed I.I. Micro-invasive glaucoma surgery: Current perspectives and future directions. Curr. Opin. Ophthalmol. 2012;23:96–104. Source
39. Pereira I.C.F., van de Wijdeven R., Wyss H.M., Beckers H.J.M., den Toonder J.M.J. Conventional glaucoma implants and the new MIGS devices: A comprehensive review of current options and future directions. Eye. 2021;35:3202–3221. Source
40. Shah M. Micro-invasive glaucoma surgery—An interventional glaucoma revolution. Eye Vis. 2019;6:29. Source
41. Samuelson T.W., Katz L.J., Wells J.M., Duh Y.J., Giamporcaro J.E. Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. Ophthalmology. 2011;118:459–467. Source
42. Ahmed IIK, et al. Long-term Outcomes from the HORIZON Randomized Trial for a Schlemm’s Canal Microstent in Combination Cataract and Glaucoma Surgery. Ophthalmology. 2022;129:742–751. Source
43. Montesano G, et al. Five-Year Visual Field Outcomes of the HORIZON Trial. American Journal of Ophthalmology. 2023;251:143–155. Source
44. Murthy S.K., Damji K.F., Pan Y., Hodge W.G. Trabeculectomy and phacotrabeculectomy, with mitomycin-C, show similar two-year target IOP outcomes. Can. J. Ophthalmol. 2006;41:51–59. Source
45. Tsai H.Y., Liu C.J., Cheng C.Y. Combined trabeculectomy and cataract extraction versus trabeculectomy alone in primary angle-closure glaucoma. Br. J. Ophthalmol. 2009;93:943–948. Source
46. Tzu J.H., Shah C.T., Galor A., Junk A.K., Sastry A., Wellik S.R. Refractive outcomes of combined cataract and glaucoma surgery. J. Glaucoma. 2015;24:161–164. Source
47. Vaideanu D., Mandal K., Hildreth A., Fraser S.G., Phelan P.S. Visual and refractive outcome of one-site phacotrabeculectomy compared with temporal approach phacoemulsification. Clin. Ophthalmol. 2008;2:569–574. Source
48. Ong C., Nongpiur M., Peter L., Perera S.A. Combined Approach to Phacoemulsification and Trabeculectomy Results in Less Ideal Refractive Outcomes Compared With the Sequential Approach. J. Glaucoma. 2016;25:e873–e878. Source
49. Hugkulstone C.E. Changes in keratometry following trabeculectomy. Br. J. Ophthalmol. 1991;75:217–218. Source
50. Bae H.W., Lee Y.H., Kim D.W., Lee T., Hong S., Seong G.J., Kim C.Y. Effect of trabeculectomy on the accuracy of intraocular lens calculations in patients with open-angle glaucoma. Clin. Exp. Ophthalmol. 2016;44:465–471. Source
51. Muallem M.S., Nelson G.A., Osmanovic S., Quinones R., Viana M., Edward D.P. Predicted refraction versus refraction outcome in cataract surgery after trabeculectomy. J. Glaucoma. 2009;18:284–287. Source
52. Zhang N., Tsai P.L., Catoira-Boyle Y.P., Morgan L.S., Hoop J.S., Cantor L.B., WuDunn D. The effect of prior trabeculectomy on refractive outcomes of cataract surgery. Am. J. Ophthalmol. 2013;155:858–863. Source
53. Yeh O.L., Bojikian K.D., Slabaugh M.A., Chen P.P. Refractive Outcome of Cataract Surgery in Eyes With Prior Trabeculectomy: Risk Factors for Postoperative Myopia. J. Glaucoma. 2017;26:65–70. Source
54. Iwasaki K., Takamura Y., Arimura S., Tsuji T., Matsumura T., Gozawa M., Inatani M. Prospective Cohort Study on Refractive Changes after Trabeculectomy. J. Ophthalmol. 2019;2019:4731653. Source
55. Cashwell L.F., Martin C.A. Axial length decrease accompanying successful glaucoma filtration surgery. Ophthalmology. 1999;106:2307–2311. Source
56. Kook M.S., Kim H.B., Lee S.U. Short-term effect of mitomycin-C augmented trabeculectomy on axial length and corneal astigmatism. J. Cataract Refract. Surg. 2001;27:518–523. Source
57. Pakravan M., Alvani A., Esfandiari H., Ghahari E., Yaseri M. Post-trabeculectomy ocular biometric changes. Clin. Exp. Optom. 2017;100:128–132. Source
58. Husain R., Li W., Gazzard G., Foster P.J., Chew P.T., Oen F.T., Phillips R., Khaw P.T., Seah S.K., Aung T. Longitudinal changes in anterior chamber depth and axial length in Asian subjects after trabeculectomy surgery. Br. J. Ophthalmol. 2013;97:852–856. Source
59. Francis B.A., Wang M., Lei H., Du L.T., Minckler D.S., Green R.L., Roland C. Changes in axial length following trabeculectomy and glaucoma drainage device surgery. Br. J. Ophthalmol. 2005;89:17–20. Source
60. Dickens M.A., Cashwell L.F. Long-term effect of cataract extraction on the function of an established filtering bleb. Ophthalmic Surg. Lasers. 1996;27:9–14. Source
61. Zhang X., Vadoothker S., Munir W.M., Saeedi O. Ocular Surface Disease and Glaucoma Medications: A Clinical Approach. Eye Contact Lens. 2019;45:11–18. Source
62. Skalicky S.E., Goldberg I., McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am. J. Ophthalmol. 2012;153:1–9.e2. Source
63. Starr C.E., Gupta P.K., Farid M., Beckman K.A., Chan C.C., Yeu E., Gomes J.A.P., Ayers B.D., Berdahl J.P., Holland E.J., et al. An algorithm for the preoperative diagnosis and treatment of ocular surface disorders. J. Cataract Refract. Surg. 2019;45:669–684. Source
64. Drolsum L., Haaskjold E., Davanger M. Pseudoexfoliation syndrome and extracapsular cataract extraction. Acta Ophthalmol. 1993;71:765–770. Source
65. Scorolli L., Scorolli L., Campos E.C., Bassein L., Meduri R.A. Pseudoexfoliation syndrome: A cohort study on intraoperative complications in cataract surgery. Ophthalmologica. 1998;212:278–280. Source
66. Shingleton B.J., Neo Y.N., Cvintal V., Shaikh A.M., Liberman P., O’Donoghue M.W. Outcome of phacoemulsification and intraocular lens implantion in eyes with pseudoexfoliation and weak zonules. Acta Ophthalmol. 2017;95:182–187. Source
67. Jehan F.S., Mamalis N., Crandall A.S. Spontaneous late dislocation of intraocular lens within the capsular bag in pseudoexfoliation patients. Ophthalmology. 2001;108:1727–1731. Source
68. Shingleton B.J., Marvin A.C., Heier J.S., O’Donoghue M.W., Laul A., Wolff B., Rowland A. Pseudoexfoliation: High risk factors for zonule weakness and concurrent vitrectomy during phacoemulsification. J. Cataract Refract. Surg. 2010;36:1261–1269. Source
69. Manoharan N., Patnaik J.L., Bonnell L.N., SooHoo J.R., Pantcheva M.B., Kahook M.Y., Wagner B.D., Lynch A.M., Seibold L.K. Refractive outcomes of phacoemulsification cataract surgery in glaucoma patients. J. Cataract Refract. Surg. 2018;44:348–354. Source
70. Mehta R., Tomatzu S., Cao D., Pleet A., Mokhur A., Aref A.A., Vajaranant T.S. Refractive Outcomes for Combined Phacoemulsification and Glaucoma Drainage Procedure. Ophthalmol. Ther. 2022;11:311–320. Source
71. Kang Y.S., Sung M.S., Heo H., Ji Y.S., Park S.W. Long-term outcomes of prediction error after combined phacoemulsification and trabeculectomy in glaucoma patients. BMC Ophthalmol. 2021;21:60. Source
72. Scott R.A., Ferguson T.J., Stephens J.D., Berdahl J.P. Refractive outcomes after trabecular microbypass stent with cataract extraction in open-angle glaucoma. Clin. Ophthalmol. 2019;13:1331–1340. Source
73. Ioannidis A.S., Töteberg-Harms M., Hamann T., Hodge C. Refractive Outcomes After Trabecular Micro-Bypass Stents (iStent Inject) with Cataract Extraction in Open-Angle Glaucoma. Clin. Ophthalmol. 2020;14:517–524. Source
74. Luebke J., Boehringer D., Neuburger M., Anton A., Wecker T., Cakir B., Reinhard T., Jordan J.F. Refractive and visual outcomes after combined cataract and trabectome surgery: A report on the possible influences of combining cataract and trabectome surgery on refractive and visual outcomes. Graefes Arch. Clin. Exp. Ophthalmol. 2015;253:419–423. Source
75. Sieck E.G., Capitena Young C.E., Epstein R.S., SooHoo J.R., Pantcheva M.B., Patnaik J.L., Lynch A.M., Kahook M.Y., Seibold L.K. Refractive outcomes among glaucoma patients undergoing phacoemulsification cataract extraction with and without Kahook Dual Blade goniotomy. Eye Vis. 2019;6:28. Source
76. Sarkisian S.R., Jr., Radcliffe N., Harasymowycz P., Vold S., Patrianakos T., Zhang A., Herndon L., Brubaker J., Moster R., Francis B. Visual outcomes of combined cataract surgery and minimally invasive glaucoma surgery. J. Cataract Refract. Surg. 2020;46:1422–1432. Source
77. Inoue M., Bissen-Miyajima H., Yoshino M., Suzuki T. Wavy horizontal artifacts on optical coherence tomography line-scanning images caused by diffractive multifocal intraocular lenses. J. Cataract Refract. Surg. 2009;35:1239–1243. Source
78. Armstrong J.J., Wasiuta T., Kiatos E., Malvankar-Mehta M., Hutnik C.M.L. The Effects of Phacoemulsification on Intraocular Pressure and Topical Medication Use in Patients With Glaucoma: A Systematic Review and Meta-analysis of 3-Year Data. J. Glaucoma. 2017;26:511–522. Source
79. Benekos K., Katsanos A., Haidich A.B., Dastiridou A., Nikolaidou A., Konstas A.G. The Effect of Phacoemulsification on the Intraocular Pressure of Patients With Open Angle Glaucoma: A Systematic Review and Meta-Analysis. J. Glaucoma. 2024;33:576–586. Source
80. Mansberger S.L., Gordon M.O., Jampel H., et al. Reduction in intraocular pressure after cataract extraction: the Ocular Hypertension Treatment Study. Ophthalmology. 2012;119:1826–1831. Source
81. Otarola F., Virgili G., Shah A., Hu K., Bunce C., Gazzard G. Ab interno trabecular bypass surgery with Schlemm’s canal microstent (Hydrus) for open angle glaucoma. Cochrane Database Syst. Rev. 2020;3:CD012740. Source
82. Le J.T., Bicket A.K., Wang L., Li T. Ab interno trabecular bypass surgery with iStent for open-angle glaucoma. Cochrane Database Syst. Rev. 2019;3:CD012743. Source
83. Hong A.S.Y., Ang B.C.H., Dorairaj E., Dorairaj S. Premium Intraocular Lenses in Glaucoma: A Systematic Review. Bioengineering (Basel). 2023;10:993. Source
84. National Eye Institute. Cataract Surgery. Updated December 5, 2024. Source
85. Azuara-Blanco A., Burr J., Ramsay C., et al. Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial. Lancet. 2016;388:1389–1397. Source
86. Samuelson T.W., Sarkisian S.R., Lubeck D.M., et al. Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results. Ophthalmology. 2019;126:811–821. Source
87. Masis M., Mineault P.J., Phan E., Lin S.C. The role of phacoemulsification in glaucoma therapy: A systematic review and meta-analysis. Surv. Ophthalmol. 2018;63:700–710. Source
88. Song Z., Li Y., Wang Y., Shi J., Zhou L., Ding X. iStent combined with phacoemulsification versus phacoemulsification alone in open-angle glaucoma: a meta-analysis by medication washout status. BMC Ophthalmol. 2026;26:483. Source
89. Li L., Wang X., Liu C., Wang S., Wang X. Incidence Rate of Secondary Glaucoma Following Congenital Cataract Surgery: An In-Depth Systematic Review and Meta-Analysis. Am. J. Ophthalmol. 2024;265:176–188. Source

Medical disclaimer

Medical Disclaimer: This article provides general education. It is not medical advice, a diagnosis or a personal treatment plan, and it does not establish a doctor-patient relationship. Do not start, stop or change any prescribed medicine or treatment without the clinicians responsible for your care. Sudden vision loss, a new shower of floaters, flashes, a curtain or shadow in your vision, or a painful red eye needs urgent eye care.